Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

Shots:

• The P-III REMDACTA study involves assessing Actemra/RoActemra (tocilizumab) + Veklury (remdesivir) vs PBO + Veklury in hospitalized patients with severe COVID-19 pneumonia receiving SOC
• The study did not meet its 1EPs i.e. improvement in time to hospital discharge up to day28 and failed to meet its 2EPs compared to Veklury alone. The findings will be submitted for publication in a peer-reviewed journal
• Roche will continue to evaluate data from REMDACTA, COVACTA, and EMPACTA studies as well as other studies of Actemra in COVID-19 pneumonia

Click here ­to­ read full press release/ article | Ref: Roche | Image: CNBC